CVE-2022-39238

Improper Authentication in Arvados when using PAM as identity provider

Description

Arvados is an open source platform for managing and analyzing biomedical big data. In versions prior to 2.4.3, when using Portable Authentication Modules (PAM) for user authentication, if a user presented valid credentials but the account is disabled or otherwise not allowed to access the host (such as an expired password), it would still be accepted for access to Arvados. Other authentication methods (LDAP, OpenID Connect) supported by Arvados are not affected by this flaw. This issue is patched in version 2.4.3. Workaround for this issue is to migrate to a different authentication method supported by Arvados, such as LDAP.

Category

4.2
CVSS
Severity: Medium
CVSS 3.1 •
EPSS 0.06%
Third-Party Advisory github.com
Affected: arvados arvados
Published at:
Updated at:

References

Frequently Asked Questions

What is the severity of CVE-2022-39238?
CVE-2022-39238 has been scored as a medium severity vulnerability.
How to fix CVE-2022-39238?
To fix CVE-2022-39238, make sure you are using an up-to-date version of the affected component(s) by checking the vendor release notes. As for now, there are no other specific guidelines available.
Is CVE-2022-39238 being actively exploited in the wild?
As for now, there are no information to confirm that CVE-2022-39238 is being actively exploited. According to its EPSS score, there is a ~0% probability that this vulnerability will be exploited by malicious actors in the next 30 days.
What software or system is affected by CVE-2022-39238?
CVE-2022-39238 affects arvados arvados.
This platform uses data from the NIST NVD, MITRE CVE, MITRE CWE, First.org and CISA KEV but is not endorsed or certified by these entities. CVE is a registred trademark of the MITRE Corporation and the authoritative source of CVE content is MITRE's CVE web site. CWE is a registred trademark of the MITRE Corporation and the authoritative source of CWE content is MITRE's CWE web site.
© 2025 Under My Watch. All Rights Reserved.